Business
Exelixis Submits Zanzalintinib to FDA, Bolstering Oncology Pipeline with Key Colorectal Cancer Candidate
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.